Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials
Rudwaleit M, Brown MA, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, et al. (2024)
Rheumatology 63(1): P163.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Rudwaleit, MartinUniBi;
Brown, Matthew A.;
van Gaalen, Floris Alexander;
Haroon, Nigil;
Gensler, Lianne S.;
Fleurinck, Carmen;
Marten, Alexander;
Massow, Ute;
de Peyrecave, Natasha;
Vaux, Thomas;
White, Katy;
Deodhar, Atul
Alle
Alle
Einrichtung
Erscheinungsjahr
2024
Serien- oder Zeitschriftentitel
Rheumatology
Band
63
Ausgabe
1
Art.-Nr.
P163
Konferenz
Annual Conference of the British-Society-for-Rheumatology (BSR)
Konferenzort
Liverpool, England
Konferenzdatum
2024-04-24 – 2024-04-26
ISSN
1462-0324
eISSN
1462-0332
Page URI
https://pub.uni-bielefeld.de/record/2999535
Zitieren
Rudwaleit M, Brown MA, van Gaalen FA, et al. Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials. Rheumatology. 2024;63(1): P163.
Rudwaleit, M., Brown, M. A., van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., et al. (2024). Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials. Rheumatology, 63(1), P163. https://doi.org/10.1093/rheumatology/keae163.202
Rudwaleit, Martin, Brown, Matthew A., van Gaalen, Floris Alexander, Haroon, Nigil, Gensler, Lianne S., Fleurinck, Carmen, Marten, Alexander, et al. 2024. “Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials”, Rheumatology, 63 (1): P163.
Rudwaleit, M., Brown, M. A., van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., Massow, U., de Peyrecave, N., Vaux, T., et al. (2024). Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials. Rheumatology 63:P163.
Rudwaleit, M., et al., 2024. Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials. Rheumatology, 63(1): P163.
M. Rudwaleit, et al., “Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials”, Rheumatology, vol. 63, 2024, : P163.
Rudwaleit, M., Brown, M.A., van Gaalen, F.A., Haroon, N., Gensler, L.S., Fleurinck, C., Marten, A., Massow, U., de Peyrecave, N., Vaux, T., White, K., Deodhar, A., McGonagle, D., van der Horst-Bruinsma, I.: Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials. Rheumatology. 63, : P163 (2024).
Rudwaleit, Martin, Brown, Matthew A., van Gaalen, Floris Alexander, Haroon, Nigil, Gensler, Lianne S., Fleurinck, Carmen, Marten, Alexander, Massow, Ute, de Peyrecave, Natasha, Vaux, Thomas, White, Katy, Deodhar, Atul, McGonagle, Dennis, and van der Horst-Bruinsma, Irene. “Low Uveitis Rates in Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2B/3 Trials”. Rheumatology 63.1 (2024): P163.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar